Our tumor-selective technology unleashes the power of immuno-oncology therapy

Xilio’s proprietary technology allows us to create novel immunotherapies that preferentially bind their targets in tumors while minimizing activity in healthy non-tumor tissues. To engineer our tumor-selective therapies, we start with a highly potent cytokine or antibody which is then inactivated by fusing it to a “blocking domain”. The blocking domain contains a cleavage site that can be cut by a protein called a protease. The blocking domain inhibits the binding of the molecule to its target(s) thereby inhibiting the function of the molecule until it is cleaved by the proteases which are found predominantly in the tumor microenvironment. This results in a tumor-selective biologic. This approach is intended to bring the benefits of immuno-oncology therapy to patients by minimizing toxicity while enhancing anti-tumor efficacy.